Researchers from Quretech Bio AB (Quretech Bio) in Umeå, who were awarded a research grant of approximately SEK 25 million in the summer, have been awarded additional funding of just over SEK 17 million this autumn (made up of SEK 7.5 million from the Swedish Research Council, SEK 8 million from the Erling Persson Family Foundation and SEK 2.1 million from Umeå University).
UBI Company Quretech Bio has reached a milestone in its development.
Recently, the company took its first investment capital and a cunning business development partner – a local player in Västerbotten.
Quretech, Hiloprobe and Inficure made the 30th of March a day to remember for Umeå Biotech Incubator. Beeing at three different events, in three parts of Sweden – they all managed to take home the main prize. An unprecedented hat trick that shows how strong the startup portfolio from Umeå really is.
Despite the name, the Biotech Umeå Investment Day is not only about raising money and not only strict biotech anymore. This year’s event had a fair representation of innovations from ICT, digital health and chemical. And it seems that the investors are also widening their scope and contributing with more value than just capital to upcoming startups.
The business coaches at Umeå Biotech Incubator have collected an impressive know-how over the years. With their inside position of some of the most innovative medical solusions they know how to get a life science company to thrive and grow.
QureTech Bio AB, a start-up at Umeå Biotech Incubator, developing first line drugs to combat antibiotic resistance and infectious diseases, won the BIO-Europe Spring Start-up Slam, in competition with 16 other presentations from 16 other Swedish life sciences start-up companies.